ITRM

Iterum Therapeutics PLC

ITRM, USA

Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

https://www.iterumtx.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ITRM
stock
ITRM

Iterum Therapeutics faces Nasdaq listing compliance challenge MSN

Read more →
ITRM
stock
ITRM

Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 Stock Titan

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$5.5

Analyst Picks

Strong Buy

0

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-2.79

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

121.65 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-27.63 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-2,015.43 %

Low ≤ 5%

High ≥ 15%

Investors

* Institutions hold a combined 5.12% of the total shares of Iterum Therapeutics PLC

1.

Renaissance Technologies Corp

(1.0567%)

since

2025/06/30

2.

Squarepoint Ops LLC

(1.023%)

since

2025/06/30

3.

Sabby Management LLC

(0.9646%)

since

2025/06/30

4.

New Leaf Venture Partners, L.L.C.

(0.7726%)

since

2025/06/30

5.

Apollon Financial LLC

(0.5604%)

since

2025/06/30

6.

Resources Investment Advisors Inc

(0.3605%)

since

2025/06/30

7.

Jane Street Group LLC

(0.2081%)

since

2025/06/30

8.

Two Sigma Investments LLC

(0.0565%)

since

2025/06/30

9.

Geode Capital Management, LLC

(0.0277%)

since

2025/06/30

10.

Fidelity Nasdaq Composite Index

(0.0277%)

since

2025/07/31

11.

Alpine Partners VI, LLC

(0.0224%)

since

2025/06/30

12.

Morgan Stanley - Brokerage Accounts

(0.021%)

since

2025/06/30

13.

UBS Group AG

(0.0197%)

since

2025/06/30

14.

Activest Wealth Management

(0.0003%)

since

2025/06/30

15.

Wells Fargo & Co

(0.0002%)

since

2025/06/30

16.

SBI Securities Co Ltd

(0%)

since

2025/06/30

18.

Royal Bank of Canada

(0%)

since

2025/06/30

19.

HM Payson & Co

(0%)

since

2025/03/31

20.

Tower Research Capital LLC

(0%)

since

2025/03/31

21.

Barclays PLC

(0%)

since

2025/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.01

Latest Release

Date

2025-09-30

EPS Actual

-0.2

EPS Estimate

-0.21

EPS Difference

0.01

Surprise Percent

4.7619%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.